Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.41 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28583314 | 0.91 | USP30 (0.46) | F10F2USP30 | |
| SCHEMBL25017557 | 0.89 | KDM4E (0.44) | F10USP30 | |
| SCHEMBL28578446 | 0.88 | F10 (0.38) | F10ACSS2F2CNR2USP30 | |
| SCHEMBL31689683 | 0.88 | F10 (0.38) | F10ACSS2F2CNR2USP30 | |
| SCHEMBL25017640 | 0.88 | F10 (0.38) | F10ACSS2F2CNR2USP30 | |
| SCHEMBL25015886 | 0.88 | F10 (0.43) | F10F2 | |
| SCHEMBL25016727 | 0.88 | F10 (0.47) | F10F2 | |
| SCHEMBL25017881 | 0.88 | F10 (0.47) | F10F2 | |
| SCHEMBL25017634 | 0.88 | F10 (0.39) | F10F2CNR2USP30 | |
| SCHEMBL25016346 | 0.88 | F10 (0.38) | F10F2CNR2USP30DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | F10 1548/4885ACSS2 1949/4885F2 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.